Pulmonary alveolar proteinosis (PAP) is a lung disorder which was first described in 1958 by Rosen et al. and is indeed rare disease with a prevalence of 0
Introduction
Pulmonary alveolar proteinosis (PAP) was first described in 1958 by Rosen et al. as an infrequently seen disorder in which an amorphous, insoluble, lipoproteinaceous material tends to accumulate in the alveolar spaces, causing impairment of gas exchange [1] . Although the first reported cases were felt to be idiopathic, there have been subsequent reports suggesting that PAP could be a secondary phenomenon, resulting from exposure to silica, silicates, aluminium, fibreglass particles, and infectious agents such as Pneumocystis jirovecii, Nocardia, and mycobacteria, as well as associated with haematological malignancies. We report the case of a man who developed PAP syndrome following a 2-year exposure to silica dust and subsequently reviewed the world literature where 363 cases were found.
Case Report
A 52-year-old white male with a 60 pack-year history of cigarette smoking presented with progressive dyspnoea on exertion for 18 months. He had worked in an environment where other workers were placing tiles and cutting floors, without wearing a mask. He had a long-standing cough with whitish sputum production, but denied fever, chills, weight loss, night sweats, and other symptoms.
Physical examination revealed a mildly dyspnoeic patient with normal vital signs; heart auscultation was normal; bibasilar fine late inspiratory rales involving half the way up in both lung fields were heard. Laboratory analyses showed haemoglobin (Hb) 17 (Fig. 1) . Fiberoptic bronchoscopy failed to reveal any endobronchial lesion but yielded biopsies disclosing alveoli filled with periodic acid of Schiff (PAS)-positive lipoproteinaceous material and refringent particles compatible with silicates, and negative cultures ( Fig. 2A, B) . A therapeutic whole lung lavage (WLL) was carried out, resulting is an immediate improvement in symptoms as well as in gas exchange. 
Discussion
This case supports the hypothesis that PAP should not be considered idiopathic until we exclude all the occupational aetiologies. Indeed, the relationship between the occupational exposure and the pulmonary reaction is evident in this patient. The intra-alveolar accumulation of PASpositive material designated as PAP, has been reported to occur occasionally in workers exposed to high concentrations of fine particulate silica. This condition was first reported in 1969 by Buechner et al. [2] .
When humans and animals inhale high concentrations of silica over a short period of time, the lining cells of the airways are damaged and a lipid-rich protein exudate accumulates, obliterating the air spaces. These events are followed by type II pneumocyte hypertrophy and hyperplasia, and increased production of phospholipid. In an experimental model, production of dipalmitoyl lecithin increased threefold, while the elimination of the material decreased. Under these circumstances, phagocytosis and the removal of particles were impaired [3, 4] . Rats exposed to high concentration of quartz dust developed alveolar proteinosis with some foci of desquamative pneumonitis and there was a great deal of aggregated silica in that proteinaceous material [5] . Since 1980 there have been several cases published in the English literature of PAP with silicosis and we think that some cases could have been assumed to be idiopathic PAP [6] . This case report of silica dust exposure coexisting with PAP, and the experimental finding that inhaled fine silica dust in animals can cause a similar disease [7] , support the hypothesis that inhaled dust is responsible for the development of PAP, which may not be just a rare idiopathic disease entity, but perhaps a mere, somewhat uncommon pulmonary reaction to a noxious agent. Abraham and McEven, using scanning electron microscopy, demonstrated the presence of inorganic particulates in histological specimens from patients previously diagnosed with PAP [8] , and they also found that the count of birefringent particles was significantly higher in patients with PAP than in control history and accumulation of inorganic particles in the gas spaces of the lungs. Therefore, it is possible that PAP has multiple causes and that inhaled dusts is one of them.
A literature review was done using Medline. Three hundred and sixty-three cases were obtained in 36 manuscripts. The chart was arranged chronologically and contained the number of cases per study, the average age in each study, the type of PAP, the way the diagnosis was made, the treatment given, and the survival. Table 1 shows the compilation of 363 chronologically arranged cases worldwide from 1988 to 2014. The age at the diagnosis varied from 1 to 79 years. PAP was classified into three groups regarding the aetiology: autoimmune or idiopathic (293 cases of 352 classifiable cases, which represents 83% of the cases), secondary (56 of the 352, which stands for 16% of the classifiable cases), and congenital (only 3 cases reported as such, which comprise 1% of the total). Twelve cases of 363 were not classifiable. PAP was diagnosed on the basis of bronchoalveolar lavage (BAL), transbronchial lung biopsy (TBLB), or open lung biopsy (OLB). Until year 2006, WLL was the only treatment for PAP and the survival was almost 100%. In 2006, oncology researchers discovered serendipitously that knockout mice deprived of granulocyte macrophage-colony stimulating factor (GM-CSF) gene or receptor developed full blown PAP, which was ameliorated by the administration of GM-CSF. Thereafter it was conceptualized that GM-CSF plays an important role in the homeostasis of surfactant production in the alveolar milieu, and then the usefulness of administering GM-CSF to improve this condition was readily acknowledged. Subsequently, a dual therapy consistent in administration of GM-CSF and WLL was established.
WLL had been the standard of therapy since the report by Ramirez [45] and consequently we managed this reported patient using that intervention. The patient was placed under general anaesthesia, and a double lumen endotracheal tube was inserted; the dependent lung was placed down, a bronchoscope was inserted and after wedging it in a distant airway, we started lavage by instilling normal saline and then suctioning intermittently. Initially we obtained a lavageate that was markedly creamy due to the high lipoproteinaceous content and subsequently it became clear. Approximately 20 L had to be suctioned to get to this point. A week later, we performed WLL of the second lung.
The double lumen endotracheal tube is a key factor because we can **obturate and ventilate one lung and work in the other one. Most of the experts use the "eyeball technique" to estimate how much of lavage is sufficient. The frequency of lavage has to be individualized.
After the advent of GM-CSF it became a major contributing factor because it was recognized that its deficiency or absence would lead to a significant accumulation of surfactant in the alveolar space. The management of PAP changed forever after this because it became customary to first try GM-CSF and use WLL only for the therapeutic failure of GM-CSF. GM-CSF has been used via inhalational, systemic, or subcutaneous delivery with comparable results.
Finally, it is of utmost importance to analyse and improve the environment of patients. Avoidance of exposure to triggering agents such as silica, mould, or any infective or toxic material is the cornerstone of management of secondary type PAP. 
